Comprehensive Drug Penalty Act

In More Harm Than Good, Carter, Boyd and MacPherson take a critical look at the current state of Canadian drug policy and raise key questions about the effects of Canada’s increasing involvement in and commitment to the “war on drugs.” A primer on Canadian drug policy, the analysis in More Harm Than Good is shaped by critical sociology and feminist perspectives on drugs and incorporates insights not only from individuals who are on the front lines of drug policy in Canada — treatment and service workers — but also from those who live with the consequences of that policy on a daily basis — people who use criminalized drugs. Finally, the authors propose realistic alternatives to today’s failed policy approach. “Your book really expanded thinking and understanding and had a big influence on students critical and reflective thought. Readings sparked rich conversations about their own hopes and wishes for the field, broader social and political responses and the impact on youth and families affected by substances.” - Stephanie McCune, University of Victoria Please note: an error occurred with the printing of this book, and one of the sidebars was not printed. It is available to download here. We sincerely apologize for this oversight.

For nearly three decades, methadone hydrochloride has been the primary means of treating opiate addiction. Today, about 115,000 people receive such treatment, and thousands more have benefited from it in the past. Even though methadone's effectiveness has been well established, its use remains controversial, a fact reflected by the extensive regulation of its manufacturing, labeling, distribution, and use. The Food and Drug Administration regulates the safety and effectiveness of methadone, as it does for all drugs, and the Drug Enforcement Administration regulates it as a controlled substance. However, methadone is also subjected to a unique additional tier of regulation that prescribes how and under what circumstances it may be used to treat opiate addiction. Federal Regulation of Methadone Treatment examines current Department of Health and Human Services standards for narcotic addiction treatment and the regulation of methadone treatment programs pursuant to those standards. The book includes an evaluation of the effect of federal regulations on the provision of methadone treatment services and an exploration of options for modifying the regulations to allow optimal clinical practice. The volume also includes an assessment of alternatives to the existing regulations.

Defenders of marijuana use may seize on the ambiguity or absence of evidence for such damage and ignore any other effects on education or safety; those opposed to marijuana use may emphasize the possibility of chronic disease that is suggested by some laboratory findings and ignore the social, political, and economic costs of fighting a well-established custom. The Committee wishes to make clear what it regards as the limits of this report for the selection of policy alteratives. Scientific judgment can estimate the prevalence of different kinds of use, risks to health, economic costs, and the like under current policies and can try to project such estimates for new policies. It can come to some conclusions based on those estimates. But selection of an alternative is always a value-governed choice, which can ultimately be made only by the political process.

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.

A Law Commission consultation paper 'A new homicide act for England and Wales?' was published as LCCP 177 (ISBN 0117302643) in April 2006.